OBJECTIVE: To investigate immune responses of peptide-specific CD4+ and CD8+ T cells, and nonpeptide-specific Vgamma2Vdelta2+ T cells during clinical quiescence of latent Mycobacterium tuberculosis coinfection in HIV-1-infected humans. METHODS: One hundred HIV-1-infected individuals who had HIV infection only [HIV+tuberculosis-(TB-)], latent Mycobacterium tuberculosis coinfection (HIV + LTB), or active tuberculosis (HIV + TB) were recruited to measure mycobacterium purified protein derivative (PPD)-specific IFNgamma+ CD4+ and CD8+ T cells, and phosphoantigen HMBPP-specific IFNgamma+ Vgamma2Vdelta2+ T cells using enzyme-linked immunospot and intracellular cytokine staining assays. RESULTS: Both HIV + TB and HIV + LTB groups had low levels of PPD-specific IFNgamma+ CD4+ T cells regardless of CD4+ peripheral blood lymphocytes counts. However, numbers of PPD-specific IFNgamma+ CD8+ T cells in the HIV + LTB group were significantly greater than those in the HIV + TB group. Surprisingly, numbers of phosphoantigen hydroxy-3-methyl-but-2-enyl pyrophosphate-specific IFNgamma+ Vgamma2Vdelta2+ T cells in the HIV + LTB group were much greater than those in the HIV + TB group (P < 0.001). This difference was present in the subgroups of HIV + LTB whatever the levels of CD4+ T-cell counts more than 200/microl or less than 200/microl. Numbers of hydroxy-3-methyl-but-2-enyl pyrophosphate-specific IFNgamma+ Vgamma2Vdelta2+ T cells were even five times greater than those of PPD-specific IFNgamma+ CD8 T cells within the HIV + LTB group. CONCLUSION: Potent immune responses of hydroxy-3-methyl-but-2-enyl pyrophosphate-specific IFNgamma+ Vgamma2Vdelta2+ T cells and PPD-specific IFNgamma+ CD8+ T cells were detected in HIV + LTB persons but not HIV + TB patients. The robust immune responses of Vgamma2Vdelta2+ and CD8+ T effector cells were associated with the latent stage of Mycobacterium tuberculosis coinfection in HIV-1-infected humans.
OBJECTIVE: To investigate immune responses of peptide-specific CD4+ and CD8+ T cells, and nonpeptide-specific Vgamma2Vdelta2+ T cells during clinical quiescence of latent Mycobacteriumtuberculosis coinfection in HIV-1-infectedhumans. METHODS: One hundred HIV-1-infected individuals who had HIV infection only [HIV+tuberculosis-(TB-)], latent Mycobacterium tuberculosis coinfection (HIV + LTB), or active tuberculosis (HIV + TB) were recruited to measure mycobacterium purified protein derivative (PPD)-specific IFNgamma+ CD4+ and CD8+ T cells, and phosphoantigenHMBPP-specific IFNgamma+ Vgamma2Vdelta2+ T cells using enzyme-linked immunospot and intracellular cytokine staining assays. RESULTS: Both HIV + TB and HIV + LTB groups had low levels of PPD-specific IFNgamma+ CD4+ T cells regardless of CD4+ peripheral blood lymphocytes counts. However, numbers of PPD-specific IFNgamma+ CD8+ T cells in the HIV + LTB group were significantly greater than those in the HIV + TB group. Surprisingly, numbers of phosphoantigenhydroxy-3-methyl-but-2-enyl pyrophosphate-specific IFNgamma+ Vgamma2Vdelta2+ T cells in the HIV + LTB group were much greater than those in the HIV + TB group (P < 0.001). This difference was present in the subgroups of HIV + LTB whatever the levels of CD4+ T-cell counts more than 200/microl or less than 200/microl. Numbers of hydroxy-3-methyl-but-2-enyl pyrophosphate-specific IFNgamma+ Vgamma2Vdelta2+ T cells were even five times greater than those of PPD-specific IFNgamma+ CD8 T cells within the HIV + LTB group. CONCLUSION: Potent immune responses of hydroxy-3-methyl-but-2-enyl pyrophosphate-specific IFNgamma+ Vgamma2Vdelta2+ T cells and PPD-specific IFNgamma+ CD8+ T cells were detected in HIV + LTBpersons but not HIV + TBpatients. The robust immune responses of Vgamma2Vdelta2+ and CD8+ T effector cells were associated with the latent stage of Mycobacteriumtuberculosis coinfection in HIV-1-infectedhumans.
Authors: Dan Huang; Yun Shen; Liyou Qiu; Crystal Y Chen; Ling Shen; Jim Estep; Robert Hunt; Daphne Vasconcelos; George Du; Pyone Aye; Andrew A Lackner; Michelle H Larsen; William R Jacobs; Barton F Haynes; Norman L Letvin; Zheng W Chen Journal: Infect Immun Date: 2007-10-08 Impact factor: 3.441
Authors: P A Selwyn; D Hartel; V A Lewis; E E Schoenbaum; S H Vermund; R S Klein; A T Walker; G H Friedland Journal: N Engl J Med Date: 1989-03-02 Impact factor: 91.245
Authors: Yun Shen; Ling Shen; Prabhat Sehgal; Dan Huang; Liyou Qiu; George Du; Norman L Letvin; Zheng W Chen Journal: J Virol Date: 2004-12 Impact factor: 5.103
Authors: Molebogeng X Rangaka; Lavanya Diwakar; Ronnett Seldon; Gilles van Cutsem; Graeme A Meintjes; Chelsea Morroni; Priscilla Mouton; Muki S Shey; Gary Maartens; Katalin A Wilkinson; Robert J Wilkinson Journal: Clin Infect Dis Date: 2007-05-10 Impact factor: 9.079
Authors: Z W Chen; Z C Kou; C Lekutis; L Shen; D Zhou; M Halloran; J Li; J Sodroski; D Lee-Parritz; N L Letvin Journal: J Exp Med Date: 1995-07-01 Impact factor: 14.307
Authors: Mei Xia; Danny C Hesser; Prithwiraj De; Isaac G Sakala; Charles T Spencer; Jay S Kirkwood; Getahun Abate; Delphi Chatterjee; Karen M Dobos; Daniel F Hoft Journal: Infect Immun Date: 2016-08-19 Impact factor: 3.441